Compare · DFTX vs LXRX
DFTX vs LXRX
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Lexicon Pharmaceuticals Inc. (LXRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. DFTX focuses on Medicinal Chemicals and Botanical Products, while LXRX focuses on Biotechnology: Pharmaceutical Preparations.
- DFTX is the larger of the two at $3.88B, about 5.7x LXRX ($681.2M).
- DFTX has been more active in the news (9 items in the past 4 weeks vs 7 for LXRX).
- DFTX has more recent analyst coverage (8 ratings vs 6 for LXRX).
- Company
- Definium Therapeutics Inc.
- Lexicon Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $3.88B
- $681.2M
- 1M return
- -21.27%
- -
- 1Y return
- +141.13%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 9
- 7
- Recent ratings
- 8
- 6
Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Latest DFTX
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
- Definium Therapeutics to Participate at Upcoming Investor Conferences
- Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
Latest LXRX
- Lexicon Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London
- New Data at 2026 American Heart Association Scientific Sessions Highlight Cardiovascular Effects of Sotagliflozin on Thrombus Formation and in Hypertrophic Cardiomyopathy
- Chief Executive Officer Exton Michael bought $49,999 worth of shares (30,064 units at $1.66), increasing direct ownership by 10% to 328,496 units (SEC Form 4)
- SEC Form 10-Q filed by Lexicon Pharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Lexicon Pharmaceuticals Inc.
- Lexicon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
- Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
- Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
- Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease